Clinical Trials

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04246177 2025-12-17

LEAP-012

480 enrolled

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT04949256 2025-12-15

MK-7902-014

864 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

480 enrolled

Cholangiocarcinoma

NCT06371157 2025-03-12

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

469 enrolled

Phase 3 Active not recruiting

Carcinoma, Hepatocellular

NCT05301842 2025-01-15

EMERALD-3

760 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05910970 2024-01-23

PREVENT-2

200 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06201065 2024-01-11

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

200 enrolled

Phase 3 Not yet recruiting

Carcinoma, Hepatocellular

NCT06089382 2023-10-18

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

104 enrolled

Carcinoma, Hepatocellular

NCT05608200 2023-05-31

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

427 enrolled

Carcinoma, Hepatocellular

NCT05608213 2022-11-08

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

187 enrolled

Carcinoma, Hepatocellular

NCT05220020 2022-05-19

TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

299 enrolled

954 enrolled 19 charts 1 FDA

Carcinoma, Hepatocellular

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

Carcinoma, Hepatocellular, Neoplasms

NCT05056337 2021-09-24

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

220 enrolled

Carcinoma, Hepatocellular

NCT04229355 2021-02-09

DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

90 enrolled

Carcinoma, Hepatocellular

NCT04053972 2019-08-13

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

377 enrolled

Carcinoma, Hepatocellular

NCT04053985 2019-08-13

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

206 enrolled

Carcinoma, Hepatocellular

NCT03744247 2019-05-02

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Phase 3 Withdrawn

Carcinoma, Hepatocellular

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Phase 3 Withdrawn

Carcinoma, Hepatocellular

NCT03775395 2019-01-03

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC

250 enrolled